How Much Does Chemotherapy for breast cancer Cost in Italy?
Chemotherapy for breast cancer in Italy typically costs from $6,500 to $12,500. The total price depends on the drug regimen, cycle frequency, and the facility tier. In the US, similar treatments cost around $45,000 on average. Italy offers savings of approximately 79%. Basic inclusions usually cover the medication, administration fees, and medical monitoring during the infusion.
- Targeted biological therapies: May increase standard treatment costs by over 300%.
- Combined immunotherapy: Integrated protocols often cost approximately 400% more than standard chemotherapy.
- Major medical hubs: Facilities in Milan and Rome often charge premium rates for international patients.
- Regional variations: Costs for sessions in northern Italy may be higher than southern regions.
Bookimed Expert Insight: Choosing a research-focused hospital like San Raffaele in Milan offers exceptional value. This IRCCS-accredited facility combines clinical care with advanced translational research. The Breast Cancer Group, led by Dr. Bianchini Giampaolo, participates in over 100 clinical trials. This gives patients access to innovative drug combinations and immunotherapy. International patients benefit from university-level expertise at private-sector speeds. High volumes of 52,000 annual operations ensure refined clinical protocols.
| Italy | Turkey | Austria | |
|---|---|---|---|
| Chemotherapy for breast cancer | ≈ $6,500 | from $4,700 | ≈ $9,500 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Chemotherapy for breast cancer upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Chemotherapy for breast cancer and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Chemotherapy for breast cancer journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Chemotherapy for breast cancer Clinics in Italy: 1 Verified Option and Prices
Chemotherapy for breast cancer Overview in Italy
Day 1: Arrival
- Arrive in the country and check into the hotel.
- Rest and acclimate to the new environment.
Day 2: Pre-Operation
- Undergo initial consultation with the oncologist.
- Have a full medical check-up.
- Take an audiometry test for hearing baseline.
- Additional tests if needed, based on your health condition.
Day 3: Chemotherapy
- Admitted to the hospital for chemotherapy treatment.
- Undergo Chemotherapy which usually lasts for a few hours.
- No anesthesia is required as the process is painless.
- Post-treatment, rest at the hospital under medical supervision.
Day 4: Post-Operation
- Consultation with oncologist to discuss the treatment effects.
- Stay at the hospital for continued monitoring and care.
Day 5: Departure
- Discharge from the hospital and transfer to the hotel.
- Rest and recovery at the hotel before travelling back.
Week 1-4: Rehabilitation
- Regular follow-ups with your local oncologist.
- Gradual return to work and other activities as strength allows.
- Engage in mild physical exercises under guidance.
- Noticeable improvement in health and decrease in treatment side-effects.
Week 8: Final Result
- Complete recovery and return to normal lifestyle.
Please note that the process may vary based on individual health condition and response to the treatment.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Bianchini Giampaolo
Head of Breast Cancer Group at San Raffaele – Dr. Bianchini has co-investigated 100+ clinical trials and published 45+ papers on breast cancer.
- 21 years specializing in breast cancer treatment
- Leads clinical translational and immunotherapy research
- Co-inventor of a patent for personalized drug combinations
- Trained at MD Anderson Cancer Center in the US
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews



Share this content
Anna Leonova
Fast Facts about Chemotherapy for breast cancer

Chemotherapy for breast cancer
Chemotherapy for breast cancer is a systemic treatment using drugs to destroy cancer cells in the body.
FAQ about Chemotherapy for breast cancer in Italy
When is chemotherapy recommended for breast-cancer patients in Italy?
Italian oncologists recommend chemotherapy for breast cancer based on aggressive subtypes like Triple-Negative or HER2-positive status and advanced tumor staging. Treatment protocols at centers like San Raffaele in Milan follow AIOM guidelines, utilizing genomic testing and Ki-67 markers to assess high-risk recurrence before or after surgery.
- Biological subtypes: Mandatory for aggressive Triple-Negative and HER2-positive cancers to improve prognosis.
- High-risk markers: Recommended for Luminal-like tumors with high Ki-67 proliferation indexes.
- Tumor size: Often required for tumors exceeding 2 centimeters or involving lymph nodes.
- Neoadjuvant therapy: Used before surgery for stages IIB–IIIC to shrink locally advanced disease.
Bookimed Expert Insight: Italian research hospitals like San Raffaele offer a distinct advantage through their IRCCS status, which blends high-volume clinical care with active research. Dr. Bianchini Giampaolo, who leads the Breast Cancer Group there, has co-led over 100 clinical trials. This integration means patients often access innovative drug combinations and personalized medicine protocols not yet standard in general hospitals, while saving up to 79% compared to US costs.
Which chemotherapy regimens are used in Italian centres?
Italian oncology centers utilize chemotherapy regimens following AIOM (Associazione Italiana di Oncologia Medica) guidelines. Common protocols for breast cancer include AC/EC combinations followed by taxanes. Specialized centers like San Raffaele in Milan also implement metronomic chemotherapy and targeted HER2-positive treatments like Trastuzumab and T-DM1.
- Systemic protocols: Adjuvant and neoadjuvant therapy includes AC (Adriamycin/Cyclophosphamide) or EC (Epirubicin/Cyclophosphamide).
- Metronomic therapy: Preferred for metastatic cases using Vinorelbine, Cyclophosphamide, or Capecitabine-based regimens.
- Targeted agents: HER2-positive patients receive Trastuzumab, Pertuzumab, or T-DM1 alongside standard chemotherapy.
- Clinical trials: Leading centers integrate immunotherapy and patented drug combinations into trial-based treatment.
Bookimed Expert Insight: San Raffaele stands out because it combines clinical assistance with high-level research. Head of the Breast Cancer Group, Dr. Bianchini Giampaolo, is a co-investigator in over 100 clinical trials. This clinical-research bridge means patients often access the latest patented drug combinations before they become global standards. This expertise reflects the clinic IRCCS accreditation awarded only to Italy's best research hospitals.
Patient Consensus: Patients value the high standard of care in Milan. Many highlight the importance of following official AIOM guidelines for consistent results. They recommend connecting with local breast cancer support groups for navigated care within the Italian system.
How are Italian clinicians deciding whether an ER-positive, node-negative patient needs chemotherapy after surgery?
Italian clinicians determine chemotherapy needs by combining clinicopathological risk factors with genomic assays. Experts evaluate tumor grade, Ki-67 proliferation levels, and age under Italian Association of Medical Oncology (AIOM) guidelines. Genomic tests like Oncotype DX typically allow up to 30% of patients to safely avoid chemotherapy.
- Risk assessment: Clinicians evaluate tumor size, grade 3 status, and the Ki-67 proliferation index.
- Genomic testing: Oncotype DX, MammaPrint, and Prosigna identify high or low genomic recurrence risks.
- Reimbursement status: The Italian National Health System reimburses genomic assays for intermediate-risk clinical cases.
- Age factors: Younger patients under 35 years often receive chemotherapy for added ovarian suppression.
Bookimed Expert Insight: Data shows that top Italian institutions like San Raffaele in Milan integrate heavy research into daily practice. Dr. Bianchini Giampaolo at San Raffaele has co-invented patents specifically to identify which patients benefit from drug combinations. This level of translational research means Italian protocols often prioritize avoiding overtreatment compared to standard global practices.
Patient Consensus: Patients emphasize getting Ki-67 and genomic results early to change treatment plans. Many reports suggest consulting major Milan centers to reduce wait times for these critical tests.
What HER2-directed agents are reimbursed in Italy and under what conditions?
Italy fully reimburses HER2-directed agents like Trastuzumab, Pertuzumab, and Trastuzumab Deruxtecan through the National Health Service (SSN). Eligibility follows Italian Medicines Agency (AIFA) criteria. Access requires registration in clinical monitoring registers. These Class H drugs are administered exclusively within hospital settings for metastatic or high-risk cases.
- Drug classification: Classified as Class H for hospital-only administration under specialist oncology supervision.
- Reimbursement conditions: Enrollment in AIFA monitoring registers ensures strict adherence to clinical eligibility.
- Pathologic response: Adjuvant Trastuzumab reimbursement mandates a complete pathologic response for one-year coverage.
- HER2-low criteria: Trastuzumab Deruxtecan is now reimbursed for unresectable or metastatic HER2-low cases.
Bookimed Expert Insight: Top Italian research centers like San Raffaele in Milan provide rapid access to newly reimbursed therapies. Dr. Bianchini Giampaolo there leads breast cancer research and tracks real-time AIFA updates. This is vital because reimbursement for HER2-low status is a recent and complex regulatory shift. Choosing a research-focused IRCCS hospital ensures access to the latest approved funding protocols.
Patient Consensus: Local support groups recommend consulting hospital pharmacists directly about current AIFA lists. Patients emphasize that oncologists handle all registration paperwork for seamless SSN coverage during treatment.
How long must a medical traveller stay in Italy to complete a chemotherapy cycle?
Medical travelers should plan for a 13 to 14 day stay in Italy for a single chemotherapy cycle. This timeframe covers the administration day and a critical observation period. It ensures patients manage immediate side effects before returning home or continuing therapy.
- Cycle duration: Standard cycles last 21 days with treatment following a recovery rest period.
- Treatment window: Drug administration typically requires 1 to 5 days depending on the regimen.
- Hospital observation: Complex protocols might require 1 to 5 nights for hydration or monitoring.
- Visa legalities: Italian medical visas cover the full therapy duration and allow for extensions.
Bookimed Expert Insight: While a single cycle requires 2 weeks, full breast cancer protocols average 4 to 8 cycles. Prestigious centers like San Raffaele in Milan use IRCCS research status to offer advanced trials. Their oncologists often trained at the MD Anderson Cancer Center, bridging US-standard care with Italian logistics.
Patient Consensus: Travelers emphasize contacting clinics directly since protocols are highly individualized. Coordinating with your home oncologist is essential to maintain treatment continuity after returning from Italy.
Essential questions to ask the Italian oncologist before starting systemic therapy?
When consulting an Italian oncologist about systemic therapy, prioritize questions regarding the treatment's intent, the specific genomic rationale for the drug choice, and clinical trial eligibility. Patients should confirm the logistics of administration, such as the use of PICC lines, and establish protocols for managing severe side effects within the Italian healthcare structure.
- Treatment objective: Ask if the goal is curative, neoadjuvant, or palliative for your specific stage.
- Clinical trials: Inquire about trials through the IRCCS network to access cutting-edge immunotherapy options.
- Fertility preservation: Request a fertility specialist referral immediately if you are under age 40.
- Generic policy: Confirm if biosimilars or generics will be substituted mid-cycle during your treatment course.
Bookimed Expert Insight: Data shows that Milan hubs like San Raffaele offer unique access to translational research through IRCCS status. Patients often find that specialists here, such as Dr. Bianchini Giampaolo, use laboratory research to personalize drug combinations. Ask your oncologist directly if their facility holds IRCCS accreditation before finalizing your systemic therapy plan.
Patient Consensus: Patients emphasize the need to demand specific anti-nausea and neuropathy prevention protocols upfront. Many suggest preparing for private fertility or genomic testing costs as public system timelines can be tight.



